

Avraham Raz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11966733/publications.pdf>

Version: 2024-02-01

111
papers

11,307
citations

24978

57
h-index

32761

100
g-index

112
all docs

112
docs citations

112
times ranked

7673
citing authors

#	ARTICLE	IF	CITATIONS
1	The Complex Biological Effects of Pectin: Galectin-3 Targeting as Potential Human Health Improvement?. <i>Biomolecules</i> , 2022, 12, 289.	1.8	15
2	MYH9 binds to dNTPs via deoxyribose moiety and plays an important role in DNA synthesis. <i>Oncotarget</i> , 2022, 13, 534-550.	0.8	3
3	Galectin-3: an immune checkpoint target for musculoskeletal tumor patients. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 297-302.	2.7	4
4	Galectin-3 N-terminal tail prolines modulate cell activity and glycan-mediated oligomerization/phase separation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	24
5	Amplification of autocrine motility factor and its receptor in multiple myeloma and other musculoskeletal tumors. <i>Journal of Bone Oncology</i> , 2020, 23, 100308.	1.0	3
6	Autocrine motility factor and its receptor expression in musculoskeletal tumors. <i>Journal of Bone Oncology</i> , 2020, 24, 100318.	1.0	8
7	Pleiotropic Effects of Modified Citrus Pectin. <i>Nutrients</i> , 2019, 11, 2619.	1.7	68
8	GP78 Cooperates with Dual-Specificity Phosphatase 1 To Stimulate Epidermal Growth Factor Receptor-Mediated Extracellular Signal-Regulated Kinase Signaling. <i>Molecular and Cellular Biology</i> , 2019, 39, .	1.1	11
9	Migration and proliferation of cancer cells in culture are differentially affected by molecular size of modified citrus pectin. <i>Carbohydrate Polymers</i> , 2019, 211, 141-151.	5.1	33
10	Professor Lina M. Obeid (1955â€“2019). <i>Cancer and Metastasis Reviews</i> , 2019, 38, 839-839.	2.7	2
11	The ubiquitin specific protease USP34 protects the ubiquitin ligase gp78 from proteasomal degradation. <i>Biochemical and Biophysical Research Communications</i> , 2019, 509, 348-353.	1.0	5
12	Galectin-3 and cancer stemness. <i>Glycobiology</i> , 2018, 28, 172-181.	1.3	100
13	Cancer Self-Defense: An Immune Stealth. <i>Cancer Research</i> , 2017, 77, 5441-5444.	0.4	11
14	Ripening-induced chemical modifications of papaya pectin inhibit cancer cell proliferation. <i>Scientific Reports</i> , 2017, 7, 16564.	1.6	47
15	The influence of PSA autoantibodies in prostate cancer patients: a prospective clinical study-II. <i>Oncotarget</i> , 2017, 8, 17643-17650.	0.8	8
16	Positive associations between galectin-3 and PSA levels in prostate cancer patients: a prospective clinical study-I. <i>Oncotarget</i> , 2016, 7, 82266-82272.	0.8	18
17	Galectin-3 in bone tumor microenvironment: a beacon for individual skeletal metastasis management. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 333-346.	2.7	23
18	Galectin-3 Cleavage Alters Bone Remodeling: Different Outcomes in Breast and Prostate Cancer Skeletal Metastasis. <i>Cancer Research</i> , 2016, 76, 1391-1402.	0.4	62

#	ARTICLE	IF	CITATIONS
19	Glycodendrimers and Modified ELISAs: Tools to Elucidate Multivalent Interactions of Galectins 1 and 3. <i>Molecules</i> , 2015, 20, 7059-7096.	1.7	21
20	Extracellular galectin-3 programs multidrug resistance through Na ⁺ /K ⁺ -ATPase and P-glycoprotein signaling. <i>Oncotarget</i> , 2015, 6, 19592-19604.	0.8	23
21	Galectin-3 induces cell migration via a calcium-sensitive MAPK/ERK1/2 pathway. <i>Oncotarget</i> , 2014, 5, 2077-2084.	0.8	54
22	Galectin-3 Inhibits Osteoblast Differentiation through Notch Signaling. <i>Neoplasia</i> , 2014, 16, 939-949.	2.3	71
23	Galectin-3 in angiogenesis and metastasis. <i>Glycobiology</i> , 2014, 24, 886-891.	1.3	167
24	Nuclear transport of galectin-3 and its therapeutic implications. <i>Seminars in Cancer Biology</i> , 2014, 27, 30-38.	4.3	60
25	Multivalent scaffolds induce galectin-3 aggregation into nanoparticles. <i>Beilstein Journal of Organic Chemistry</i> , 2014, 10, 1570-1577.	1.3	26
26	Galectin-3 leads to attenuation of apoptosis through Bax heterodimerization in human thyroid carcinoma cells. <i>Oncotarget</i> , 2014, 5, 9992-10001.	0.8	45
27	Galectin-3: a possible complementary marker to the PSA blood test. <i>Oncotarget</i> , 2013, 4, 542-549.	0.8	53
28	Galectin-3 Contributes to Melanoma Growth and Metastasis via Regulation of NFAT1 and Autotaxin. <i>Cancer Research</i> , 2012, 72, 5757-5766.	0.4	79
29	Tyrosine-phosphorylated Galectin-3 Protein Is Resistant to Prostate-specific Antigen (PSA) Cleavage. <i>Journal of Biological Chemistry</i> , 2012, 287, 5192-5198.	1.6	38
30	Galectin-3 Binding and Metastasis. <i>Methods in Molecular Biology</i> , 2012, 878, 251-266.	0.4	24
31	Galectin-3 Mediates Cross-Talk between K-Ras and Let-7c Tumor Suppressor microRNA. <i>PLoS ONE</i> , 2011, 6, e27490.	1.1	35
32	Galectin-3: A novel substrate for c-Abl kinase. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2010, 1803, 1198-1205.	1.9	27
33	Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer. <i>International Journal of Cancer</i> , 2010, 127, 2530-2541.	2.3	92
34	Modified citrus pectin anti-metastatic properties: one bullet, multiple targets. <i>Carbohydrate Research</i> , 2009, 344, 1788-1791.	1.1	248
35	Regulation of Tumor Progression by Extracellular Galectin-3. <i>Cancer Microenvironment</i> , 2008, 1, 43-51.	3.1	106
36	Galectin-3 regulates RasGRP4-mediated activation of N-Ras and H-Ras. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2008, 1783, 985-993.	1.9	21

#	ARTICLE	IF	CITATIONS
37	Racial Disparity in Breast Cancer and Functional Germ Line Mutation in Galectin-3 (rs4644): A Pilot Study. <i>Cancer Research</i> , 2008, 68, 10045-10050.	0.4	58
38	Biological Modulation by Lectins and Their Ligands in Tumor Progression and Metastasis. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2008, 8, 22-36.	0.9	81
39	On the Role of Galectin-3 in Cancer Metastasis : From the Bench to the Clinic and Back. <i>Nihon Kikan Shokudoka Gakkai Kaiho</i> , 2008, 59, 91-91.	0.0	0
40	Galectin-3 Cleavage: A Novel Surrogate Marker for Matrix Metalloproteinase Activity in Growing Breast Cancers. <i>Cancer Research</i> , 2007, 67, 11760-11768.	0.4	88
41	Phosphorylated Galectin-3 Mediates Tumor Necrosis Factor-related Apoptosis-inducing Ligand Signaling by Regulating Phosphatase and Tensin Homologue Deleted on Chromosome 10 in Human Breast Carcinoma Cells. <i>Journal of Biological Chemistry</i> , 2007, 282, 21337-21348.	1.6	41
42	The role of galectin-3 in cancer drug resistance. <i>Drug Resistance Updates</i> , 2007, 10, 101-108.	6.5	129
43	Galectin-3 as a Potential Therapeutic Target in Tumors Arising from Malignant Endothelia. <i>Neoplasia</i> , 2007, 9, 662-670.	2.3	89
44	Inhibition of breast tumor growth and angiogenesis by a medicinal herb: <i>Ocimum gratissimum</i> . <i>International Journal of Cancer</i> , 2007, 121, 884-894.	2.3	63
45	Galectin-3 in apoptosis, a novel therapeutic target. <i>Journal of Bioenergetics and Biomembranes</i> , 2007, 39, 79-84.	1.0	108
46	Dr. Fidler, I.J.â€”Forty years of metastasis research. <i>Cancer and Metastasis Reviews</i> , 2007, 26, 357-358.	2.7	0
47	Work accomplishmentsâ€”Isaiah J. Fidler. <i>Cancer and Metastasis Reviews</i> , 2007, 26, 353-355.	2.7	0
48	Regulation of cancer-related gene expression by galectin-3 and the molecular mechanism of its nuclear import pathway. <i>Cancer and Metastasis Reviews</i> , 2007, 26, 605-610.	2.7	71
49	On the Role of Galectins in Signal Transduction. <i>Methods in Enzymology</i> , 2006, 417, 273-289.	0.4	42
50	Galectin Binding to Mgat5-Modified N-Glycans Regulates Fibronectin Matrix Remodeling in Tumor Cells. <i>Molecular and Cellular Biology</i> , 2006, 26, 3181-3193.	1.1	185
51	Galectin-3 Expression Is Associated with Tumor Progression and Pattern of Sun Exposure in Melanoma. <i>Clinical Cancer Research</i> , 2006, 12, 6709-6715.	3.2	84
52	Galectin-3 Regulates Mitochondrial Stability and Antiapoptotic Function in Response to Anticancer Drug in Prostate Cancer. <i>Cancer Research</i> , 2006, 66, 3114-3119.	0.4	114
53	Importin-mediated Nuclear Translocation of Galectin-3. <i>Journal of Biological Chemistry</i> , 2006, 281, 39649-39659.	1.6	41
54	Galectin-3 Inhibits Tumor Necrosis Factorâ€”Related Apoptosis-Inducing Ligandâ€”Induced Apoptosis by Activating Akt in Human Bladder Carcinoma Cells. <i>Cancer Research</i> , 2005, 65, 7546-7553.	0.4	118

#	ARTICLE	IF	CITATIONS
55	Implication of Galectin-3 in Wnt Signaling. <i>Cancer Research</i> , 2005, 65, 3535-3537.	0.4	126
56	Effects of DNA Methylation on Galectin-3 Expression in Pituitary Tumors. <i>Cancer Research</i> , 2005, 65, 1136-1140.	0.4	62
57	Phosphorylation of Galectin-3 Contributes to Malignant Transformation of Human Epithelial Cells via Modulation of Unique Sets of Genes. <i>Cancer Research</i> , 2005, 65, 10767-10775.	0.4	43
58	Galectin-3 Regulates a Molecular Switch from N-Ras to K-Ras Usage in Human Breast Carcinoma Cells. <i>Cancer Research</i> , 2005, 65, 7292-7300.	0.4	100
59	Sugar recognition and metastasis: From birth of a research field to the clinic. <i>Cancer Biology and Therapy</i> , 2005, 4, 679-681.	1.5	0
60	Mechanical Entrapment Is Insufficient and Intercellular Adhesion Is Essential for Metastatic Cell Arrest in Distant Organs. <i>Neoplasia</i> , 2005, 7, 522-527.	2.3	160
61	Galectin-3, a Novel Binding Partner of β -Catenin. <i>Cancer Research</i> , 2004, 64, 6363-6367.	0.4	206
62	Nuclear Export of Phosphorylated Galectin-3 Regulates Its Antiapoptotic Activity in Response to Chemotherapeutic Drugs. <i>Molecular and Cellular Biology</i> , 2004, 24, 4395-4406.	1.1	195
63	Autocrine Motility Factor Signaling Enhances Pancreatic Cancer Metastasis. <i>Clinical Cancer Research</i> , 2004, 10, 7775-7784.	3.2	77
64	Galectins and urological cancer. <i>Journal of Cellular Biochemistry</i> , 2004, 91, 118-124.	1.2	19
65	Proteases, Extracellular Matrix, and Cancer. <i>American Journal of Pathology</i> , 2004, 164, 1131-1139.	1.9	202
66	Alterations in Galectin-3 Expression and Distribution Correlate with Breast Cancer Progression. <i>American Journal of Pathology</i> , 2004, 165, 1931-1941.	1.9	88
67	Malignant transformation of thyroid follicular cells by galectin-3. <i>Cancer Letters</i> , 2003, 195, 111-119.	3.2	79
68	CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. <i>Cancer Research</i> , 2003, 63, 8302-11.	0.4	280
69	Galectin-3 Phosphorylation Is Required for Its Anti-apoptotic Function and Cell Cycle Arrest. <i>Journal of Biological Chemistry</i> , 2002, 277, 6852-6857.	1.6	209
70	Galectin-3 Translocates to the Perinuclear Membranes and Inhibits Cytochrome c Release from the Mitochondria. <i>Journal of Biological Chemistry</i> , 2002, 277, 15819-15827.	1.6	270
71	On the role of cell surface carbohydrates and their binding proteins (lectins) in tumor metastasis. , 2002, , 109-141.		0
72	Inhibition of Human Cancer Cell Growth and Metastasis in Nude Mice by Oral Intake of Modified Citrus Pectin. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1854-1862.	3.0	368

#	ARTICLE	IF	CITATIONS
73	Carbohydrate-binding proteins in cancer, and their ligands as therapeutic agents. Trends in Molecular Medicine, 2002, 8, 187-192.	3.5	147
74	Galectin-3 enhances cyclin D1 promoter activity through SP1 and a cAMP-responsive element in human breast epithelial cells. Oncogene, 2002, 21, 8001-8010.	2.6	128
75	Galectin-3 and metastasis. Glycoconjugate Journal, 2002, 19, 543-549.	1.4	268
76	Galectin-3 Protects Human Breast Carcinoma Cells against Nitric Oxide-Induced Apoptosis. American Journal of Pathology, 2001, 159, 1055-1060.	1.9	113
77	On the role of cell surface carbohydrates and their binding proteins (lectins) in tumor metastasis. Cancer and Metastasis Reviews, 2001, 20, 245-277.	2.7	255
78	Carbohydrate-recognition and angiogenesis. Cancer and Metastasis Reviews, 2000, 19, 51-57.	2.7	35
79	Phosphorylation of the \hat{I}^2 -Galactoside-binding Protein Galectin-3 Modulates Binding to Its Ligands. Journal of Biological Chemistry, 2000, 275, 36311-36315.	1.6	96
80	Galectin-3 Induces Endothelial Cell Morphogenesis and Angiogenesis. American Journal of Pathology, 2000, 156, 899-909.	1.9	402
81	Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. , 1999, 85, 2475-2484.		146
82	Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. , 1999, 85, 2475.		13
83	Galectin-3 and L1 retrotransposons in human breast carcinomas. Breast Cancer Research and Treatment, 1998, 49, 171-183.	1.1	40
84	Autocrine motility factor and the extracellular matrix. I. Coordinate regulation of melanoma cell adhesion, spreading and migration involves focal contact reorganization. , 1998, 76, 120-128.		21
85	Autocrine motility factor and the extracellular matrix. II. Degradation or remodeling of substratum components directs the motile response of tumor cells. , 1998, 76, 129-135.		17
86	Metastasis of human colon cancer is altered by modifying expression of the \hat{I}^2 -galactoside-binding protein galectin 3. Gastroenterology, 1998, 115, 287-296.	0.6	162
87	Galectin-3 Stimulates Cell Proliferation. Experimental Cell Research, 1998, 245, 294-302.	1.2	168
88	Autocrine motility factor and the extracellular matrix. I. Coordinate regulation of melanoma cell adhesion, spreading and migration involves focal contact reorganization. , 1998, 76, 120.		1
89	Tumor cell motility and metastasis. Pathology and Oncology Research, 1997, 3, 230-254.	0.9	21
90	Expression of the endogenous galactose-binding protein galectin-3 correlates with the malignant potential of tumors in the central nervous system. Cancer, 1997, 80, 776-787.	2.0	155

#	ARTICLE	IF	CITATIONS
91	Expression of the endogenous galactose-binding protein galectin-3 correlates with the malignant potential of tumors in the central nervous system. , 1997, 80, 776.		10
92	Galectin-3 in Tumor Metastasis.. Trends in Glycoscience and Glycotechnology, 1997, 9, 69-75.	0.0	20
93	Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon. Cancer, 1995, 75, 2818-2826.	2.0	199
94	Loss of cell-contact regulation and altered responses to autocrine motility factor correlate with increased malignancy in prostate cancer cells. International Journal of Cancer, 1995, 63, 100-105.	2.3	32
95	Galectins: A family of animal β -galactoside-binding lectins. Cell, 1994, 76, 597-598.	13.5	1,150
96	Galectin-3 Is a Novel Substrate for Human Matrix Metalloproteinases-2 and -9. Biochemistry, 1994, 33, 14109-14114.	1.2	251
97	Regulation of melanoma-cell motility by the lipoxygenase metabolite 12-(S)-hete. International Journal of Cancer, 1993, 55, 1003-1010.	2.3	71
98	Structure-function relationship of a recombinant human galactoside-binding protein. Biochemistry, 1993, 32, 4455-4460.	1.2	90
99	Modulation of the Lung Colonization of B16-F1 Melanoma Cells by Citrus Pectin. Journal of the National Cancer Institute, 1992, 84, 438-442.	3.0	178
100	Evidence for the role of 34-kDa galactoside-binding lectin in transformation and metastasis. International Journal of Cancer, 1990, 46, 871-877.	2.3	174
101	Differential expression of cell adhesion molecules in variants of K1735 melanoma cells differing in metastatic capacity. International Journal of Cancer, 1989, 43, 709-712.	2.3	66
102	Lectins in Cancer Cells. Annals of the New York Academy of Sciences, 1988, 551, 385-398.	1.8	101
103	Actin Organization, Cell Motility, and Metastasis. Advances in Experimental Medicine and Biology, 1988, 233, 227-233.	0.8	9
104	Adhesive Properties of Metastasizing Tumour Cells. Novartis Foundation Symposium, 1988, 141, 109-122.	1.2	2
105	Endogenous galactoside-binding lectins: a new class of functional tumor cell surface molecules related to metastasis. Cancer and Metastasis Reviews, 1987, 6, 433-452.	2.7	297
106	Cell-contact and-architecture of malignant cells and their relationship to metastasis. Cancer and Metastasis Reviews, 1987, 6, 3-21.	2.7	67
107	Transformation-related changes in the expression of endogenous cell lectins. International Journal of Cancer, 1987, 39, 353-360.	2.3	104
108	Cell shape modulation alters glycosylation of a metastatic melanoma cell-surface antigen. International Journal of Cancer, 1987, 40, 396-402.	2.3	58

#	ARTICLE	IF	CITATIONS
109	The establishment and characterization of a new balb/c angiosarcoma tumor system. International Journal of Cancer, 1985, 36, 261-272.	2.3	17
110	Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature, 1984, 312, 646-649.	13.7	768
111	Growth control and cell spreading: Differential response in preneoplastic and in metastatic cell variants. International Journal of Cancer, 1982, 29, 711-715.	2.3	24